

Dear Sir/Madam

Thank you for your Freedom of Information request concerning new oral anti-coagulants (NOACs).

The Trust can provide the following information:

- Numbers of patients treated with the new oral anti-coagulation treatments:

Drug	Number patients treated in the last 3 months
Rivaroxaban (Xarelto)	50
Dabigatran (Pradaxa)	5
Apixaban (Eliquis)	1

- If possible, please split the patients by the following diagnosis;  
Not able to provide this data as not recorded in this format

Drug	Acute cardiac syndrome (ACS)	Venous Thrombo-embolism (VTE)	Prophylaxis of VTE
Rivaroxaban (Xarelto)			
Dabigatran (Pradaxa)			
Apixaban (Eliquis)			

- What is the usual dose/strength for the following treatments, for each of the indications listed:

Drug	Typical doses for VTE prophylaxis	Typical dose for ACS	Typical dose for AF
Rivaroxaban (Xarelto)	Knee: 10mg od for 14 days Hip: 10mg od for 5 weeks		20mg od
Dabigatran (Pradaxa)	Knee: 150mg – 220mg od for 9 days Hip: 150mg-220mg od for 27-34 days		110mg bd
Apixaban (Eliquis)	Knee: 2.5mg bd 10-14 days Hip: 2.5mg bd 32-38days		2.5mg – 5mg bd

- Please fill in the following table relating to dispensed items in the last 3 months:

Drug & strength	Number of items dispensed from pharmacy
Rivaroxaban (Xarelto) 20mg	0
Rivaroxaban (Xarelto) 10mg	59
Rivaroxaban (Xarelto) 15mg	8
Dabigatran (Pradaxa) 110mg	10
Dabigatran (Pradaxa) 75mg	1
Dabigatran (Pradaxa) 150mg	0
Apixaban (Eliquis) 2.5mg	1
Apixaban (Eliquis) 5mg	0

If you have any queries about this response please contact the information governance manager at [foi@homerton.nhs.uk](mailto:foi@homerton.nhs.uk) , in the first instance. If, following that, you still have any concerns, you may contact the Information Commissioner either by letter, FOI/EIR Complaints resolution, Wycliffe House, Water Lane, Wilmslow, Cheshire SM9 5AF, or by email [www.informationcommissioner.gov.uk](http://www.informationcommissioner.gov.uk) to take them further.

#### Copyright Statement

The material provided is subject to the HUHFT's copyright unless otherwise indicated. Unless expressly indicated on the material to the contrary, it may be reproduced free of charge in any format or medium, provided it is reproduced accurately and not used in a misleading manner. Where any of the copyright items are being re-published or copied to others, you must identify the source of the material and acknowledge the copyright status. Permission to reproduce material does not extend to any material accessed through the Publication Scheme that is the copyright of third parties. You must obtain authorisation to reproduce such material from the copyright holders concerned.

Yours sincerely

James Cook  
Information Governance Administrator

Mike Dunne  
Information Governance Manager/Deputy Calidcott Guardian